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Abstract 
Advances in immune checkpoint therapy and targeted therapy have led to improvement in overall survival for 
patients with advanced melanoma. Single agent checkpoint PD-1 blockade and combination with BRAF/MEK tar-
geted therapy demonstrated benefit in overall survival (OS). Superior response rates have been demonstrated with 
combined PD-1/CTLA-4 blockade, with a significant OS benefit compared with single-agent PD-1 blockade. Despite 
the progress in diagnosis of melanocytic lesions, correct classification of patients, selection of appropriate adju-
vant and systemic therapies, and prediction of response to therapy remain real challenges in melanoma. Improved 
understanding of the tumor microenvironment, tumor immunity and response to therapy has prompted extensive 
translational and clinical research in melanoma. Development of novel biomarker platforms may help to improve 
diagnostics and predictive accuracy for selection of patients for specific treatment. There is a growing evidence that 
genomic and immune features of pre-treatment tumor biopsies may correlate with response in patients with mela-
noma and other cancers but they have yet to be fully characterized and implemented clinically. Overall, the progress 
in melanoma therapeutics and translational research will help to optimize treatment regimens to overcome resistance 
and develop robust biomarkers to guide clinical decision-making. During the Melanoma Bridge meeting (December 
3rd–5th, 2020, Italy) we reviewed the currently approved systemic and local therapies for advanced melanoma and 
discussed novel biomarker strategies and advances in precision medicine.
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Introduction
The treatment of metastatic melanoma has undergone 
a dramatic transformation over the past decade with 
the advent of molecular targeted therapy and immu-
notherapy. Therapeutic approaches targeting mutated 
BRAF 600 mutations (e.g. vemurafenib, dabrafenib, and 
encorafenib) are Food and Drug Administration (FDA)-
approved drugs that have been developed as inhibitors of 
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inhibitors shows good efficacy against BRAF-mutant 
melanomas, patients can easily develop resistance. As a 
result, combination therapy with BRAF and MEK inhibi-
tors, including trametinib and cobimetinib, has become 
standard to inhibit melanoma growth. Direct targeting 
of NRAS oncogene is difficult, and therapies focused on 
targeting its downstream signals including MEK inhibi-
tors have been identified as potential therapy for NRAS 
mutants. Despite the success of target therapies, the ther-
apy failure in many patients suggests that much remains 
to be learned about the mechanism or response and 
resistance to these drugs.
Immune checkpoint inhibitors represent a novel class 
of drugs that have increasingly been used in melanoma 
therapy. Major advances in targeting the immune eva-
sion phase of tumors have been achieved using drugs 
that block the inhibitory check points that regulate the 
immune system, such as programmed death 1 (PD-1) 
and cytotoxic T-lymphocyte-associated antigen (CTLA-
4) and other T cell inhibitory and activating receptors. 
Dual immune checkpoint blockade with ipilimumab 
and nivolumab enhances response rates compared with 
single agent ipilimumab or nivolumab in patients with 
metastatic melanoma (response rate, 58%), and both 
nivolumab containing arms demonstrated superior over-
all survival (OS) compared with single agent ipilimumab.
Several approaches in immunotherapy that include 
monoclonal antibodies, vaccines, biochemotherapy, 
and the transfer of adoptive T cells, natural killer (NK) 
cells, dendritic cells and bispecific antibodies are cur-
rently under investigation for the treatment of mela-
noma. These treatments have the same goal as drugs that 
are already used to stimulate the proliferation of T lym-
phocytes in order to destroy tumor cells. Another form 
of immunotherapy active in cutaneous melanoma is the 
injectable agent talimogene laherparepvec (T-VEC).
While immunotherapy shows promising potential, 
predicting therapeutic response has proven difficult. 
Programmed death ligand-1 (PD-L1) has been stud-
ied as a potential marker to predict response to immu-
notherapy PD-L1. PD-L1 expression, a T cell-inflamed 
tumor microenvironment, and tumor mutation burden 
(TMB) have been shown to be associated with improved 
response rates to checkpoint blockade therapy; how-
ever, absence of expression did not rule out a chance for 
response to combined or monotherapy.
Timely diagnosis of melanoma is critical for effective 
therapy, but histopathologic diagnosis can frequently 
present significant challenges to this goal. Diagnostic 
and therapeutic molecular markers have been increas-
ingly used to assist in histopathological assessment of 
especially of histologically challenging cases. Detect-
ing molecular markers such as genetic alterations has 
emerged as an innovative diagnostic and predictive bio-
markers that guides therapeutic decisions. Biomarkers 
that are represented by gene mutations in the mitogen-
activated protein kinase (MAPK) and PI3K/AKT signal-
ing pathways (e.g. BRAF, NRAS, MEK, ERK) are the most 
common genes affected in cutaneous melanoma. The 
hallmarks mutations in uveal melanoma (e.g. GNAQ/
GNA11, BAP, SF3B1, EIF1AX) and acral melanoma (e.g. 
KIT) have also been identified. These markers are not 
only helpful for diagnosing melanoma, but also in distin-
guishing certain subtypes that can guide the selection of 
treatment and development of novel targeted therapies.
Despite the dramatic improvement in clinical outcomes 
over the past decade owing to immunotherapy and tar-
geted therapy in melanoma, not all patients respond to 
approved systemic therapies. Extensive preclinical, trans-
lational, and clinical research is ongoing to better under-
stand the mechanisms of response and resistance to 
current therapies, develop rational next-generation treat-
ments (and combinations), and develop better models of 
melanoma that will support further preclinical and trans-
lational research.
Melanoma as a model system—session
Targeting the microbiota in melanoma anti‑PD1 therapy
The composition of the gut microbiome determines the 
efficacy of cancer therapy by modulating the anti-tumor 
immune response through the training of infiltrating 
myeloid and antigen-presenting cells in the tumor. This 
has been shown in murine models, in which mice with 
distinct gut microbiota profiles exhibited differential 
tumor growth and differences in response to PD-1 block-
ade. These differences could be eliminated by cohous-
ing of animals, indicating it could be transmitted. Fecal 
microbiota transplant (FMT) together with anti-PD-1 
therapy resulted in nearly full tumor rejection in mice 
with melanoma.
The influence of the microbiome on the effect of 
immune checkpoint blockade has also been shown in sev-
eral clinical studies. In one study of melanoma patients 
treated with PD-1 inhibitors, significant differences were 
observed in the gut microbiome between responders and 
non-responders, with responders having higher diversity 
and more Ruminococcaceae bacteria [1]. These patients 
also had enhanced systemic and antitumor immunity. 
In another study, a significant association was observed 
between microbiome composition and clinical response 
to PD-1 blockade in melanoma patients, with Bifidobac-
terium longum, Collinsella aerofaciens, and Enterococcus 
faecium all more abundant in responders [2].
One issue is that different studies have identified a 
wide variety of different bacterial species that are asso-
ciated with response. In a meta-analysis of several 
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studies, metagenomics identified Ruminococcaceae, 
Lachnospiraceae, and Bifidobacteriaceae as being asso-
ciated with a response to anti-PD-1 treatment, while 
Bacteroidaceae were generally associated with a lack of 
response.
The potential role of FMT is being assessed in a phase 
II trial at the University of Pittsburgh, in which fecal sam-
ples obtained from long-term PD-1 responders is com-
bined with additional anti-PD-1 treatment in melanoma 
patients who previously failed to respond to PD-1 block-
ade [3]. To date, 16 anti-PD-1 refractory patients have 
received FMT from PD-1 responders, with one complete 
response, two partial responses and three with stable dis-
ease. Consistent with previous observations, responders 
tended to have higher frequency of Ruminococcaceae, 
Lachnospiraceae, and Bifidobacteriaceae, while Bacteroi-
daceae were more frequent in patients with disease pro-
gression. FMT induced a rapid and persistent alteration 
and instability in the microbiome composition, although 
each patient generally maintained a distinct microbiome 
based on their existing taxa before receiving FMT. The 
majority of taxa that were present in the donor but not 
the recipient colonized the donor gut and were persistent 
unless the patient was treated with antibiotics. Overall, 
the microbiota composition after FMT reflected coloni-
zation with the donor-specific taxa but perturbation of 
the microbiome resulted in altered abundance of differ-
ent taxa of both donor and recipient origin.
FMT in anti-PD-1 refractory melanoma is most likely 
to induce a response in patients with the immunological 
potential to respond but with an unfavorable microbiota 
that can be corrected. However, anti-PD-1 refractory 
patients may fail FMT for various reasons. These may 
include the absence of an adequate immunological 
response regardless of microbiota composition, the FMT 
lacking the taxa needed to improve anti-PD-1 response, 
or the FMT failing to induce a perturbation of the micro-
biome that favors a response, due either to technical 
reasons or possibly because of incompatibility between 
donor and recipient microbiome.
Prediction of response to checkpoint inhibition: is there 
a simple but not simplistic way?
A subset of patients with metastatic melanoma have 
durable responses to immunotherapy, while others 
develop potentially serious immune-related adverse 
events. Reliable biomarkers that can predict response to 
immune checkpoint inhibition are needed but remain 
elusive. PD-L1 expression, and TMB are used in the 
clinic but have limitations, as do other baseline charac-
teristics that have been proposed, e.g. lactate dehydro-
genase (LDH) and ECOG performance status. Active 
areas of research to predict immune checkpoint inhibitor 
response include biomarkers in the blood and micro-
biome, genomic profiling of the T cell regulome, auto-
antibody signatures for immune-related toxicity and 
microRNA (miRNA) profiling.
Another possible approach is to integrate machine 
learning technology on histology specimens with clinical 
data to predict immune checkpoint inhibitor response. 
Previously, our group developed a deep convolutional 
neural network pipeline that could discriminate between 
malignant and normal lung tissue. In addition, the net-
work was trained to accurately predict the most fre-
quently mutated genes in lung tumors including STK11, 
EGFR, FAT1, SETBP1, KRAS and TP53 [4]. This machine 
learning framework was then adapted to whole slide 
image analysis of tissue from patients with metastatic 
melanoma who had lymph node and/or subcutaneous 
tissue resected before first-line anti-CTLA-4 and/or anti-
PD-1 therapy [5].
Google Inception v3 was used as a foundation architec-
ture for computational image analysis. Using hematoxylin 
and eosin-stained slides, a neural network segmenta-
tion classifier was trained to identify the tumor from the 
surrounding microenvironment. Because the dataset 
included lymph node and subcutaneous tissue sections, 
the classifier was trained to identify lymphocyte clusters 
and connective tissue in addition to tumor compart-
ments. This segmentation classifier distinguished regions 
of interest with high accuracy. A response classifier was 
then trained to identify whether patients responded to 
checkpoint blockade or were resistant and progressed. 
A logistic regression classifier that combined neural net-
work output with clinical and demographic variables 
(ECOG performance status) augmented the prediction 
accuracy. Class activation mapping revealed that cell 
nuclei played an important role in the decision to classify 
samples as progressive disease or response, with more 
and larger nuclei associated with a prediction of pro-
gression. Based on these findings, machine learning on 
metastatic melanoma tissue histology shows potential for 
predicting immunotherapy response, especially if inte-
grated with clinical data.
Another approach is to assess the relationship between 
body mass index (BMI) and outcomes. Studies have sug-
gested a link between BMI and response to checkpoint 
blockade, including the counterintuitive phenomenon 
in which a high BMI seems to confer a survival benefit 
[6]. However, there are substantial discordances in these 
data. For example, we found that patients who were over-
weight or obese has similar progression-free survival 
(PFS) as patients with normal BMI [7]. However, there 
was a moderate but non-significant association between 
higher BMI and better PFS in patients receiving first-
line treatment. In addition, a significant survival benefit 
Page 4 of 18Ascierto et al. J Transl Med          (2021) 19:278 
was observed in overweight and obese patients receiv-
ing combination immunotherapy, whereas this was not 
seen in patients who received anti-PD-1 or anti-CTLA-4 
monotherapy.
One possibility is that static measurements do not con-
sider changes in body weight and nutritional intake over 
time. Moreover, in some patients a lower BMI might be 
associated with disease progression. To investigate this, 
we tested the association between BMI changes before 
the start of immunotherapy and treatment outcomes in 
patients with melanoma, lung cancer or other cancers 
[8]. A pretreatment decrease in BMI and low baseline 
prognostic nutritional index were associated with worse 
outcomes, including PFS and OS. However, baseline BMI 
category was not significantly associated with any treat-
ment outcomes, indicating that dynamic BMI changes 
rather than static assessments correlate with treatment 
response.
Immunotherapy‑induced anti‑cancer responses
The anti-cancer immune response involves B and T cell 
responses against the cancer surfaceome, which includes 
non-mutated shared antigens, mutated epitopes, and the 
extracellular domains of transmembrane proteins, as well 
as intracellular proteins released from tumor cells. There 
is considerable evidence that shared antigens are impor-
tant, and genes that are upregulated or amplified in can-
cer and are associated with worse survival outcomes are 
potential therapeutic targets. An example of an overex-
pressed normal gene is vestigial-like (VGLL)-1 that is a 
cancer-placenta antigen. VGLL-1-specific cytotoxic T 
lymphocytes (CTLs) can recognize and kill human leu-
kocyte antigen (HLA)-matched allogeneic tumor cell 
lines derived from different cancers in an antigen-spe-
cific manner, indicating that VGLL-1 may constitute an 
immunotherapeutic target in multiple cancer types [9].
Peptides that are presented on tumor human leukocyte 
antigen (HLA) molecules are mostly derived from short-
lived proteins (SLiPs) and defective ribosomal products 
(DRiPs) bound to HLA and transported to the cell sur-
face. However, these rapidly degraded products are less 
available for cross-presentation by antigen-presenting 
cells and as such are not typical targets of the immune 
system.
Blocking proteasomal degradation leads to stabiliza-
tion of DRiPs and SLiPs and the formation of autophago-
somes that contain not only DRiPs/SLiPs, but also 
damage-associated molecular patterns (DAMPs) and 
chaperone molecules that facilitate cross-presentation. 
These autophagosomes can be harvested by membrane 
disruption and fractionation to create the DRibbles 
vaccine product. The first allogeneic human DRibbles 
vaccine, DPV-001, was derived from autophagosome 
products of two non-small-cell lung cancer (NSCLC) 
cell lines, one of mixed histology and one from an ade-
nocarcinoma [10]. DPV-001 contains multiple toll-like 
receptor agonists and > 130 potential NSCLC antigens. In 
a phase II trial, patients with stage III NSCLC received 
cyclophosphamide induction therapy, before being ran-
domized to DPV-001 alone, or in combination with 
granulocyte–macrophage colony-stimulating factor or 
imiquimod. Patients receiving DPV-001 had a significant 
increase in total (CD4 and CD8) T cells versus controls 
and the increase in CD4 T cells was similar to that seen 
in patients receiving ipilimumab.
Antibody responses to over-expressed antigens were 
detected as ‘waves’ with possible co-coordination of B cell 
and T cell responses after vaccination. T cell contraction, 
a natural component of the T cell response to antigens, 
may be responsible for this anomaly. Co-stimulation with 
T cell agonists, such as OX40, GITR or 4-1BB, may aug-
ment vaccine-induced T cell expansion, maintenance, 
and function. In preclinical models, DRibbles vaccine 
and anti-OX40 co-stimulation led to tumor regression 
and improved survival in a breast cancer murine model 
[11]. Similarly, anti-GITR and anti-PD-1 antibodies in 
combination with DRibbles vaccine resulted in better 
survival in a pancreatic cancer model [12]. Three triplet 
immunotherapy trials are now ongoing; a phase 1b trial 
of multivalent autophagosome vaccine with or without 
OX40 antagonist with nivolumab in patients with triple-
negative breast cancer (NCT02737475), a phase 1b trial 
of multivalent autophagosome vaccine with or without 
GITR antagonist with anti-PD-1 in patients with head 
or neck squamous cell carcinoma (NCT04470024), and 
a trial of neoadjuvant/adjuvant GVAX pancreas vaccine 
with or without nivolumab and urelumab in patients with 
surgically resectable pancreatic cancer (NCT02451982).
The role of CD39 in melanoma
The ATP-adenosine pathway is a key modulator of innate 
and adaptive immunity within the tumor microenviron-
ment (TME). CD39 is the rate-limiting enzyme in the 
conversion of ATP to immunomodulatory adenosine. 
Extracellular adenosine in the TME favors escape from 
antitumor immunity and tumor progression. CD39 and 
adenosine receptors are upregulated in response to stim-
uli such as hypoxia, tissue damage and remodeling, and 
chronic inflammation. High levels of CD39 have been 
reported in various tumors and CD39 as a therapeutic 
target has been an active area of investigation.
CD39 blockade with the broad ectonucleotidase 
inhibitor sodium polyoxotungstate (POM-1) has shown 
improved antitumor immunity and decreased meta-
static burden in preclinical models. However, concerns 
over its lack of specificity, potential toxicity and limited 
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therapeutic half-life have hindered its clinical develop-
ment. More recently, anti-CD39 antibodies have been 
generated. A novel anti-mouse CD39 antibody, which 
specifically binds to CD39-expressing cells and potently 
inhibits CD39 ATPase activity in vitro has demonstrated 
potent activity against MC38 colon adenocarcinoma 
tumors [13]. Anti-CD39 monotherapy was as potent as 
anti-PD-1 antibody and more effective than anti-CD73 
antibodies and adenosine A2 receptor antagonists in 
this model. Anti-CD39 was also shown to sensitize anti-
PD-1 resistant tumors by increasing CD8+ T cell infil-
tration. Inhibition of CD39 enzymatic function led to 
an accumulation of extracellular ATP, which in turn led 
to an activation of myeloid cells via ATP receptor P2X7. 
The antitumor activity of anti-CD39 required CD39 and 
P2X7 co-expression on intratumor myeloid subsets and 
active interleukin (IL)-18 release to facilitate expansion of 
intratumor effector T cells.
Targeting CD39 also suppresses experimental lung car-
cinoma metastases. The antimetastatic activity of anti-
CD39 was NK cell and interferon (IFN)-γ dependent, 
and anti-CD39 enhanced IFN-γ production and CD107a 
expression in lung-infiltrating NK cells following tumor 
challenge [14]. Efficacy of anti-CD39 required enzy-
matic blockade but not FcR engagement. Anti-metastatic 
activity was dependent on the P2X7-NLRP3 inflamma-
some pathway. Anti-CD39 also combined with other 
NK cell activating agents to suppress experimental lung 
metastases.
An anti-human CD39 antibody enhanced CD4+ 
and CD8+ T cell proliferation and Th1 cytokine secre-
tion [IFN-γ, tumor necrosis factor (TNF)-α and inter-
leukin (IL)-2] in  vitro. Anti-human CD39 antibody 
also enriched intratumoral human CD8+ T cells and 
suppressed human B-cell lymphoma following autolo-
gous Epstein-Barr virus-specific T cell transfer. First-in-
human trials of the anti-CD39 antibody in patients with 
advanced cancer have recently been initiated.
Adrenergic receptors: a non‑canonical immune 
checkpoint?
The sympathetic nervous system has a role in regulating 
immune responses. The tumor is innervated by the sym-
pathetic nervous system and, in response to stress, these 
nerves secrete norepinephrine. Chronic stress may be 
detrimental because it suppresses effector immune cells 
while activating immunosuppressive cells. β-adrenergic 
receptors are expressed by many cell types in the TME 
and β-adrenergic receptor signaling acts through multi-
ple mechanisms to promote tumor survival, growth, and 
metastasis [15].
In murine models, β-adrenergic receptor antago-
nists (i.e., β-blockers) have been shown to improve the 
antitumor immune response. Chronic adrenergic sign-
aling in mice exposed to stress promotes tumor growth. 
Reducing β-adrenergic receptor signaling through the 
use of the β-blocker propranolol facilitated conversion of 
tumors to an immunologically active TME and was asso-
ciated with a significantly increased efficacy of anti-PD-1 
checkpoint blockade [16]. Retrospective studies have 
also suggested that incidental use of β-blockers is associ-
ated with better survival outcomes in cancer patients. In 
patients with metastatic melanoma who received immu-
notherapy, OS was improved by use of pan-β-blockers 
[17]. In a small prospective study of patients with stage 
IB-IIIA cutaneous melanoma, those willing to take pro-
pranolol as an adjuvant treatment had an approximately 
80% reduction in risk of recurrence versus those who did 
not take propranolol [18].
The potential of β-blockers to improve response to 
checkpoint blockade has been further explored in a phase 
I trial of propranolol and pembrolizumab in combination 
in patients with locally advanced and metastatic mela-
noma [19]. Nine patients received increasing doses of 
propranolol in combination with pembrolizumab 200 mg 
every 3 weeks. No dose-limiting toxicities were observed, 
and the most frequent treatment-related adverse events 
were rash, fatigue, and vitiligo. Objective response 
rate (ORR) was 78%. Perceived Stress Score decreased 
over time, but baseline score did not predict response. 
Responders tended to have a higher ratio of inflamma-
tory (T helper cells and CTLs) to regulatory cells [mye-
loid-derived suppressor cells (MDSCs) and regulatory T 
cells (Tregs)] in the TME at baseline, suggesting this may 
predict for outcome. Responses seen in this small study 
support the potential for pan-β-adrenergic blockade to 
synergize with anti-PD-1 inhibition. A phase II multi-
center study is currently underway.
Escape mechanisms in melanoma
HLA class 1 antigen-processing machinery (APM) 
defects are frequently present in malignant tumors. 
Mutations in the HLA class I genes themselves, abnor-
malities in their regulation and/or defects in HLA class 
I-dependent antigen processing can underlie HLA class 
I downregulation. Beta 2 Microglobulin (β2m) mutations 
inhibit HLA class I heavy chain-β2m-peptide trimo-
lecular complex formation on melanoma cells. However, 
structural defects in HLA class I heavy chain, β2m, and 
HLA class I APM components are caused by mutations 
in only a low percentage of malignancies, at most 25% of 
the total defects. Multiple regulatory mechanisms can be 
involved but the most frequent cause of HLA class I APM 
defects in malignancies is represented by abnormalities in 
epigenetic pathways. This can involve reduced HLA class 
I APM components chromatin accessibility, methylation 
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of the promoter regions of HLA class I APM components 
by DNA methyltransferases, lack of histone acetylation 
due to histone deacetylase (HDAC) overexpression, and 
histone H3 lysine 27 trimethylation (H3K27me3) by poly-
comb repressive complex 2 (PRC2). It may also be due to 
inhibition of transcription factors for HLA class I APM 
components, by downregulation of NLRC5 that acts as 
a transcriptional activator of major histocompatibility 
complex (MHC) class I gene and interferon regulatory 
factor 1 (IRF1). In addition, HLA I expression is regu-
lated by MAPK pathway including activation via EGFR, 
HER2, RAS, RAF, ALK or RET mutations/overexpression 
resulting in STAT1 inactivation. Lysosomal degradation 
of HLA class I heavy chain-β2m-peptide trimolecular 
complexes may also result in HLA class I downregulation 
on malignant cells, with autophagy resulting in expres-
sion of cargo receptor NBR1 involved in trafficking of tri-
molecular complexes to the lysosome and overexpression 
of PCSK9, a secreted protein binding to an extracellular 
region of HLA class I heavy chain that mediates endoso-
mal-lysosomal degradation of trimolecular complexes.
Most HLA class I APM defects can be corrected by 
counteracting the abnormalities in epigenetic and/or 
regulatory mechanisms. Abnormalities in the expres-
sion, regulation and/or function of components of this 
machinery have been associated with the development of 
resistances to T cell-based immunotherapies. Restoring 
sensitivity to checkpoint inhibition may be achieved by 
using targeted strategies to enhance HLA class I expres-
sion. Restoration of HLA class I APM component expres-
sion in Merkel cell carcinoma cells by treatment with 
HDAC inhibitors in vitro provided the rationale for com-
bining this approach with immune checkpoint inhibition. 
In a patient with Merkel cell carcinoma with complete 
loss of HLA class I expression and resistance to check-
point inhibition, treatment with the HDAC inhibitor 
panobinostat restored HLA class I expression, increased 
CD8+ T cell infiltration, and resulted in disease stabiliza-
tion following anti-PD-L1 treatment with avelumab.
Tumor cell-derived exosomes can also contribute to 
immune-cell dysfunction in cancer. Both normal cells 
and tumor cells in the TME produce exosomes, which are 
mixed populations of normal cell-derived and tumor cell-
derived vesicles. The tumor antigen chondroitin sulfate 
proteoglycan 4 (CSPG4) can be used as a marker to sepa-
rate exosomes released by cancer cells from exosomes 
released by non-malignant cells. Melanoma cell-derived 
exosomes inhibited C-type lectin CD69 expression, 
induced apoptosis, suppressed proliferation in CD8+ 
T cells and downregulated activating receptor NKG2D 
expression in NK cells while non-melanoma cell derived 
exosomes were enriched in immunostimulatory proteins 
[20]. Melanoma cell-derived exosomes may be a major 
mechanism of tumor-induced immune suppression and 
as a barrier to immunotherapy.
Electrochemotherapy in metastatic melanoma
Electrochemotherapy (ECT) involves the application of 
high intensity electric pulses which increase the perme-
ability of cell membranes, allowing the direct diffusion 
of cytotoxic drugs into cells. In addition to its use in skin 
cancers, ECT can be employed for the treatment of deep-
seated lesions, including in the intestinal tract, pancreas, 
liver, and bone.
ECT can provide a durable benefit in melanoma as 
shown in the study of 60 patients that reported 48% had 
a complete response, that was long-lasting after one 
ECT session, and 13 patients (45% of complete respond-
ers) disease-free after a mean duration of follow-up of 
27.5  months [21]. Similarly, a larger multicenter study, 
reported 67% 1-year OS and 74% melanoma-specific sur-
vival, indicating that ECT is a highly effective local treat-
ment for melanoma metastases in the skin [22]. Coverage 
of deep margins, previous irradiation of the treated area 
and tumor size (< 3 cm) were all significantly associated 
with complete response to ECT. More recently, 11-year 
data from 28 centers across Europe that included 987 
patients with 2482 tumor lesions were analyzed [23]. 
ORR was 85%, with 70% complete responses and 15% 
partial responses. Response rates were high across dif-
ferent histotypes, including metastases of malignant 
melanoma (82%), basal cell carcinoma (96%), breast can-
cer metastases (77%), squamous cell carcinoma (80%) 
and Kaposi’s sarcoma (98%). Higher response rates were 
achieved with lesions < 3 cm. Hexagonal electrodes were 
generally used for larger tumors, but linear array elec-
trodes provided better tumor control for tumors < 3 cm. 
Intravenous administration of bleomycin was more effec-
tive than intratumoral injection in tumors > 2 cm in size.
As with radiotherapy, ECT may induce an abscopal 
effect which suggests the potential for combining with 
immunotherapy. This may be due to the release of tumor 
antigens stimulating inflammatory response, cytokine 
production, complement activation, increased MHC class 
I expression and T cell activation as a result of check-
point inhibition. In 15 patients treated with ipilimumab 
who underwent ECT for local disease control and/or pal-
liation of cutaneous lesions, a local objective response 
was observed in 67% of patients (27% complete response) 
[24]. According to immune-related response criteria, a 
systemic response was observed in nine patients, result-
ing in a disease control rate of 60%. Response was asso-
ciated with a significant decrease in levels of circulating 
Tregs. In another study of 127 melanoma patients treated 
with ipilimumab, the addition of local peripheral treat-
ment (local irradiation, skin directed ECT or selective 
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internal radiotherapy of liver metastases) significantly 
prolonged OS [25].
A randomized study to compare ECT with wide exci-
sion in patients with local cutaneous melanoma undergo-
ing sentinel lymph node biopsy is planned.
Mechanisms of resistance and drivers 
of response—session
Translational research in the metastatic melanoma
Melanoma is a very heterogeneous disease driven by 
molecular alterations in oncogenic signaling pathways 
such as MAPK and phosphatidylinositol-3-kinase (PI3K). 
Many melanomas share features of the benign counter-
part of the melanocytic skin lesions (melanocytic naevi). 
For example, molecular characteristics of a benign naevi 
bleu overlap with ocular melanoma. Congenital naevi 
typically have NRAS mutations while acquired naevi 
have BRAF mutations.
Genetic alterations are useful biomarkers for targeted 
therapy selection, but accumulating evidence strongly 
suggests that the pathogenesis of melanoma is also 
shaped by other factors. For example, high TMB alone 
or in combination with high IFN-γ gene expression sig-
nature have shown to be predictive of prolonged relapse-
free survival (RFS) to adjuvant dabrafenib plus trametinib 
[26]. Of interest, among patients with high TMB but low 
IFN-γ gene expression signature, the benefit of targeted 
therapy was less prolonged with a sharp decrease in RFS 
after treatment discontinuation, which may imply longer 
duration of treatment is needed in this population.
Molecular alterations may be also important to under-
stand the response to immunotherapy. For example, 
TMB and gene expression-based T cell-inflamed signa-
ture were independently predictive of a positive response 
to anti-PD-1 therapy and demonstrated low correlation, 
suggesting that they reflect distinct features [27].
Recently, integrative analysis of 2658 whole-cancer 
genomes and their matching normal tissues across 38 
tumor types from the Pan-Cancer Analysis of Whole 
Genomes (PCAWG) Consortium of the International 
Cancer Genome Consortium (ICGC) and The Can-
cer Genome Atlas (TCGA) has been reported [28]. This 
revealed that the most common mutation overall was 
TP53. BRAF mutations comprise the most common 
genetic alteration in cutaneous melanoma and most 
common BRAF mutation is V600E, which represents 
80% of alterations in the gene. Mutation V600E is asso-
ciated with the superficial spreading subtype, younger 
patient age, and skin sites without chronic sun-induced 
damage (CSD). The V600K and V600R mutations are 
other known BRAF mutations. In contrast, V600K muta-
tions are correlated with skin sites with CSD, such as 
the head and neck, and patients of older age. Overall, 
single-base-substitutions and doublet-base substitu-
tions were shown to be those attributed to DNA damage 
induced by UV light, particularly enriched in these mela-
nomas [29].
Accumulating evidence suggest that the pathogenesis 
and resistance to therapy of melanoma is also shaped by 
the aberrant activity of epigenetic factors that regulate 
gene expression through the modification of DNA chro-
matin structure regulators. The combination of DNA 
and histone modifications and DNA and histone binding 
proteins create an epigenetic code that controls genome-
wide transcriptional networks. Hypermethylation affects 
key suppressor genes such as p16/INK4A. p14/ARF, 
RASSF1A and a CpG island methylator phenotype has 
been correlated with disease progression. In general, the 
interrelationship between genetic and epigenetic altera-
tions of cancer cells has been known. A gene with a high 
frequency of mutation is less commonly changed by epi-
genetic alterations, a representative example of which is 
TP53.
A multitude of cutting-edge technologies developed to 
study tumor and TME. High-dimensional mass cytom-
etry (CyTOF) allows the simultaneous measurement 
of multiple cellular markers at single-cell level. Using 
CyTOF, the frequency of CD14+ CD16+ HLA-DR hi 
monocytes was shown to be a strong predictor of pro-
gression-free and overall survival in response to anti-
PD-1 immunotherapy was shown to be a strong [30]. 
CyTOF can also be applied to tissue imaging to evaluate 
status of the inflammation of melanoma metastases, e.g., 
quantify special interactions, T cell infiltration, potential 
of T cells to interact with PD-L1 expression or the pres-
ence of tertiary lymphoid structures. Analysis of the loca-
tion of inflammatory cells in the lesion allows for spatial 
image analysis including proximity mode which can 
establish whether a tumor is cold or inflamed and help 
guide treatment decisions regarding the use of check-
point inhibitors. The next step will be to utilize these 
types of investigations in a 3D setting. This and other 
techniques will provide a huge volume of data and high-
performance medicine will require the convergence of 
human an artificial intelligence in order to develop new 
treatment algorithms (Fig. 1).
Intrinsic tumor genomic and metabolic factors leading 
to immunoresistance
Tumors use various mechanisms to resist the immune 
system, the three main ones involving the avoidance of 
detection by downregulation of immune targets (e.g., 
through β2M loss, class I downregulation), the promo-
tion of an inhibitory TME, or resisting death (e.g., the 
Pi3K pathway, glycolysis).
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One protein produced by tumors is transforming 
growth factor (TGF)-β, a ubiquitous cytokine with pleio-
tropic effects on cell growth and differentiation which 
is tumor-suppressive in early cancer stages but immu-
nosuppressive and tumor-promotional in later-stage 
disease. TGF-β limits immune responses to antigen 
presentation by inducing immune tolerance and inhib-
its the function and proliferation of T-cells. Tumors can 
be associated with very high levels of TGF-β, which has 
been shown to be elevated in the blood in patients with 
advanced stage cancer, including melanoma.
Tumor-infiltrating lymphocytes (TILs) can be engi-
neered to express the TGF-β dominant negative receptor, 
which renders T cells resistant to TGF-β in the TME. In 
a small phase I trial, 8 of 12 heavily pretreated patients 
with metastatic melanoma had a response or stable dis-
ease following adoptive transfer of these engineered 
TILs, with some of these responses being durable.
Another way by which tumors can produce a nega-
tive environment and resist death is via protein arginine 
methyltransferases (PRMT), which are upregulated in 
many tumors. PRMT catalyzes the methylation of his-
tones and non-histone proteins from S-adenosylmethio-
nine (SAM) to arginine residues. Emerging data indicates 
that arginine methylation might be a driver for the ini-
tiation and progression of cancer. Nine members of the 
PRMT family have been identified and can be divided 
into types I, II and III enzymes. PRMT1, a member of 
the type I family, is the most abundant PRMT and is 
involved in transcription activation, signal transduction, 
RNA splicing and DNA repair. PRMT1 is overexpressed 
in breast cancer, bladder cancer, pediatric acute lymph-
oblastic leukemia and in NSCLC, upregulated in lung 
cancer and glioma tissue, and associated with poor prog-
nosis of colon cancer. PRMT5 is involved in transcription 
repression, signal transduction and the piRNA pathway 
and is upregulated in lung, gastric, bladder, colon can-
cer and lymphoma, and overexpressed in breast cancer 
and epithelial ovarian cancer. Cytoplasmic expression is 
also associated with high-grade subtypes of primary lung 
adenocarcinomas. In cutaneous melanoma, upregulated 
expression of PRMT1 is associated with an immunologi-
cally cold phenotype and poor clinical outcomes. Type 
I PRMT inhibitor enhanced T cell mediated tumor kill-
ing both in vitro and in vivo and improved the antitumor 
activity of immune modulatory antibody in mice through 
increasing the infiltration of CD8 + T cells into tumor 
tissues.
Achieving durable MAPK suppression and invigorating 
anti‑melanoma T cell immunity
RAS mutant tumors have been shown to be largely 
refractory to inhibitors of the MAPK pathway. Type 
I RAF inhibitors (i.e., vemurafenib, dabrafenib, and 
Fig. 1 Multitude of cutting-edge technologies involved
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encorafenib) specifically inhibit monomeric V600 
BRAF mutants but cause paradoxical activation of the 
MAPK pathway in NRAS mutant and/or dimeric RAF-
active melanoma. The combination of type I RAF inhib-
itor plus MEK inhibitor suppresses acquired resistance 
in tumors driven by BRAF V600 mutations, although 
MAPK pathway reactivation still occurs. In contrast, 
type II RAF inhibitors inhibit monomeric and dimeric 
V600 BRAF mutants and CRAF/BRAF or CRAF/CRAF 
dimers with equal potency. As single agents, type II 
RAF inhibitors do not appear to be highly active. How-
ever, they may potentially be combined with allos-
teric MEK inhibitors to prevent the development of 
resistance.
In NRAS mutant melanoma PDX models, responses 
to daily treatment with the type II RAF inhibitor BGB-
283 or the MEK inhibitor trametinib alone were lim-
ited. However, the combination of type II RAF inhibitor 
with trametinib achieved highly durable tumor regres-
sion in all tumors [31]. This was through stabilizing 
p-MEK in RAF complexes, leading to reduced MEK 
dimerization and uncoupling of MEK or p-MEK inter-
action with ERK.
High mutational burden in both BRAF and NRAS 
mutant syngeneic mouse models prolonged MEK 
inhibitor responses in a CD8 T cell-dependent man-
ner. Systemic CD8+ T cell neutralization negated the 
increase in durability but had no effect on the develop-
ment of MEK inhibitor resistance in lower mutational 
burden tumors. This indicates that CD8+ T cells sup-
press acquired resistance to MEK inhibitors through 
neoantigen recognition. Using multiple syngeneic or 
immune-competent tumor models, including NRAS 
mutant melanoma, KRAS mutant pancreatic ductal 
adenocarcinoma and KRAS mutant colorectal can-
cer, type II RAF inhibitor plus trametinib synergisti-
cally suppressed resistance and were able to induce 
tumor regression in well-established tumors in com-
bination but not alone. In  vivo response to trametinib 
plus type II RAF inhibitor was dependent on CD8+ T 
cells. Trametinib alone resulted in a reduction in large 
T cell clones over time, while trametinib plus type II 
RAF inhibitor prevented this loss and promoted clonal 
expansion and intratumorally elicited PD-1/Ki-67-high 
CD8+ T cells. Anti-PD-L1 therapy further enhanced 
durability of response to trametinib plus type II RAF 
inhibitor in an NRAS mutant melanoma model, con-
sistent with systemic and/or intratumoral CD8+ T 
cells being an important effector of type II RAF inhibi-
tion plus MEK inhibition in immunocompetent hosts. 
Combination trials of type II RAF inhibitor plus MEK 
inhibitor plus anti-PD-1/L1 therapy may be warranted 
in RAS/MAPK-hyperactivated cancers.
Tumor mutation burden and liquid biopsies
TMB, which is defined as the number of somatic single 
nucleotide variants, InDel- and essential splicing changes 
in the complete coding region (exome) and reported as 
mutations per mega base, has been suggested as a pre-
dictive biomarker for response to checkpoint inhibitor 
therapy. In a study of 35 patients with melanoma treated 
with ipilimumab and nivolumab, TMB was significantly 
higher in responders than in non-responders and TMB-
high status (> 23.1 Mut/Mb) was associated with a sur-
vival benefit versus TMB-low or TMB-intermediate 
(TMB ≤ 23.1 Mut/Mb) [32]. Several retrospective studies 
across different tumor types, but in particular melanoma 
and NSCLC, have also reported that higher TMB is cor-
related with improved response rates and survival times 
with immune checkpoint inhibitor therapy [33]. A posi-
tive correlation between TMB and improved response to 
checkpoint blockade is not unexpected, given the higher 
the mutational load the higher the probability that neo-
antigens are presented on the tumor surface. However, 
TMB is not a prognostic factor in thick primary cutane-
ous melanoma (unpublished data).
Another potential predictive biomarker is circulating 
tumor DNA (ctDNA). In the melanoma prospective bio-
marker study, repetitive liquid biopsies were taken, cell-
free DNA was extracted and at least one driver mutation 
was monitored in each patient using digital droplet poly-
merase chain reaction from ctDNA [32]. Non-detectable 
ctDNA at baseline was a positive predictive marker for 
response to immune checkpoint inhibitors and was asso-
ciated with improved survival. Increasing ctDNA was 
almost only observed in progressive patients, with no 
increase in ctDNA during therapy also a positive predic-
tive marker for the efficacy of immune checkpoint inhibi-
tors. ctDNA remaining or becoming undetectable at first 
follow-up after 3 weeks was significantly more common 
in responders, suggesting the potential of accurately pre-
dicting treatment early after starting treatment. Other 
studies have also shown that longitudinal assessment of 
ctDNA in patients with metastatic melanoma treated 
with PD-1 inhibitors is an accurate predictor of response 
to therapy, PFS and OS [34]. The S100 serum protein 
has been the gold standard for monitoring of melanoma 
tumor progression. In an analysis of 115 plasma samples 
from 47 melanoma patients, ctDNA was shown to corre-
late with S100 and be at least as effective as S100 in pre-
dicting response to changes in tumor load.
Mechanisms of resistance to cancer immunotherapy
The T cell-inflamed and non-T cell-inflamed TME rep-
resent two categories of immune escape. T cell inflamed 
tumors are characterized by the presence of CD8+ T 
cells, expression of a chemokine signature that recruits T 
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cells into the TME and a type 1 IFN signature that sug-
gests innate immune pathways necessary to generate 
a spontaneous T cell response. These tumors are char-
acterized by inhibitory regulatory pathways that allow 
immune escape. In contrast, non-T cell-inflamed tumors 
lack this inflammatory signature with an absence of intra-
tumoral CD8+ cells and immune escape mediated by 
T cell exclusion. Most patients who respond to immu-
notherapy have T cell-inflamed tumors, with activity of 
anti-PD-1 agents associated with a T cell inflamed signa-
ture at baseline across multiple cancers. Primary resist-
ance to checkpoint blockade is most often due to a non-T 
cell inflamed TME.
Understanding the factors that regulate the degree of 
spontaneous T cell infiltration is critical to understand 
PD-1 resistance and response to immunotherapy. These 
may be tumor-intrinsic oncogenic events, environmen-
tal differences (e.g., commensal microbiota), or germline 
polymorphisms in immune regulatory genes. Secondary 
resistance to immunotherapy may also be associated with 
tumor cell-intrinsic immune-evasive oncogenic altera-
tions. For example, secondary resistance to immuno-
therapy in melanoma was associated with loss of immune 
signature and either upregulated β-catenin or PTEN 
deletion in two patients, suggesting selection for new 
oncogenic variants that mediate T cell exclusion [35].
In vitro CRISPR screening identified 2,4-dienoyl-CoA 
reductase 2 (DECR2) as an immunotherapy resistance 
gene and, in a mouse model, DECR2 knock-down tumors 
were resistant to PD-1 blockade [36]. DEC2R encodes a 
peroxisomal 2,4-dienoyl-CoA reductase and is involved 
in intracellular lipid metabolism and has a role in a cell 
death pathway distinct from apoptosis known as fer-
roptosis. Immunotherapy-activated CD8+ cells induce 
ferroptosis of tumor cells [37]. DEC2R knockdown cells 
have altered expression of ferroptosis-related genes and 
DEC2R knockdown tumor cells are relatively resistant to 
ferroptosis inducers in  vitro. DEC2R knockdown tumor 
cells also fail to generate oxidized lipids in response to 
CD8+ T cells. In melanoma samples, anti-PD-1 clinical 
benefit is associated with increased expression of DEC2R 
and decreased expression of a component of several het-
erodimeric amino acid transporter complexes SLC3A2. 
These data suggest tumor cell ferroptosis may be a major 
mechanism for T cell mediated tumor cell killing and 
may be a target pathway for improving immunotherapy 
efficacy.
T‑cell intrinsic mechanisms of resistance to PD1 checkpoint 
blockade
T cell related resistance mechanisms may explain 
why some but not all patients respond to PD-1 check-
point blockade. T cell costimulatory receptor CD28 
that  provides secondary signal for T-cell activation is a 
primary target for PD-1 mediated inhibition and rescue 
of exhausted CD28 T cells by PD-1 inhibitors is CD28 
dependent, suggesting that PD-1 directly effects the T 
cell signaling pathway.
Phospho-proteomics and flow cytometry-based analy-
sis of patient-derived T cells from responders and non-
responders to PD1 inhibitors identified mediators, 
signaling components and pathways associated with 
PD-1 checkpoint blockade resistance. Co-expression 
of T cell inhibitory receptors (BTLA and TIM3) with 
CD28 and PD-L1 was higher in patients with melanoma 
who were resistant to anti-PD-1 therapy suggesting that 
these receptors might have negative impact on melanoma 
patients outcome and be predictive biomarkers of resist-
ance to anti-PD1 pathways blockade.
BTLA and TIM3 co-expression was associated with 
resistance only in patients with CD28+ T cells. Differ-
ential expression of tyrosine phosphatase pShp-2 and 
tyrosine kinase Src pY418 was shown in PD-1 positive T 
cell subsets indicating that pShp-2 effectively antagonizes 
Src-dependent phosphorylation and negatively regulates 
signal transduction pathway in T cells. Also, T cell pro-
liferation did not substantially change after removal of 
PD-L1 in T cells from resistant patients, whereas there 
was increased proliferation in patients responding to 
anti-PD1 therapy. This indicates that the level of PD-L1+ 
cells was strongly correlated with a number of markers 
indicating a negative immune response.
It has been proposed that PD-1 suppresses initial sign-
aling following T cell receptor (TCR) ligation, which 
inhibits upregulation of CD8 binding to the TCR-pMHC 
complex and blocks further T cell activation enhance-
ment. Melanoma impaired TCR 2D affinity in a tis-
sue-restricted fashion in a mouse model, with reduced 
TCR-pMHC-CD8 binding in tumor and tumor-draining 
lymph node samples, indicating that binding is some-
how impaired in the TME. Blocking the PD-1/PD-L1 
interaction increased the 2D affinity of TCR-pMHC 
interactions, with anti-PD-1 or anti-PD-L1 therapy over-
coming the negative effect of the TME on TCR-pMHC-
CD8 affinity.
CD8-pMHC binding and Lck activity are required 
for upregulated CD8 binding to prebound TCR-pMHC 
complex. Biomembrane Force Probe measurements 
show that the activities of TCR-proximal signaling com-
ponents affect T-cell mechanosensing and sensitivity 
at the earliest stages of antigen recognition. This step in 
TCR signaling is influenced by PD-1 and other inhibitory 
receptors via Shp-1/2 targeting CD28 and Lck to directly 
suppress TCR-pMHC-CD8 binding. TCR-pMHC bind-
ing was independent of PD-1-PD-L1 interaction, but 
TCR-pMHC-CD8 binding was suppressed by PD-1 or 
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PD-L1, demonstrating negative cooperativity as fewer 
bonds formed than the sum of bonds formed by each 
interaction alone.
These data suggest that targeting these interactions and 
understanding how PD-1 signaling impacts T cell sen-
sitivity may be important for identifying new molecular 
targets to enable T-cells to overcome dysfunction during 
PD-1 checkpoint blockade and enhance the response of 
PD-1-high cells to checkpoint blockade (Fig. 2).
Targeting dendritic cells to enhance the effectiveness 
of PD1 blockade against cold tumors
Complementary targeting of the induction and effec-
tor phases of cancer immunity may be an effective 
approach in improving the effectiveness of treatments. 
Dendritic cells (DCs) are potent antigen-presenting 
cells that present tumor-specific peptides for T cell 
activation. Induction and expansion of CTLs with high 
expression of the effector-type chemokine receptors 
CXCR3 and CCR5 can be achieved through the use of 
α-type-1-polarized DC (αDC1) vaccines matured in the 
presence of type-1 and type-2 interferons. Chemokine 
modulation, e.g. with IFN-α, toll-like receptor (TLR)-3 
agonist and celecoxib, can reverse an immunosuppres-
sive chemokine profile and increase the trafficking of 
CTLs into tumors. The cytokine microenvironment 
regulates the expression of various T-cell subtypes and 
is the rationale for combining chemokine modulation 
with DC vaccines, with the vaccine expected to induce 
tumor-specific CTLs, and chemokine modulation 
expected to direct CTLs to the tumor. In theory, once 
CTLs are in the tumor, their survival and killer func-
tion can be improved through immune checkpoint 
inhibition.
IL-12 production by DCs is needed for the induction 
of tumor-specific CTLs ex vivo, and the activation of NK 
cells and Th1 cell induction. DC-produced IL-12 predicts 
prolonged PFS and/or OS in DC-vaccinated patients with 
advanced glioblastoma [38], melanoma [39] and other 
cancers [40, 41]. Autologous αDC1-induced melanoma-
specific CTLs are highly cytolytic and express high lev-
els of chemokine receptors CXCR3 and CCR5 [42]. 
Preclinical and early clinical data demonstrate that the 
chemokine-modulating regimen targeting TLR-3, type 1 
IFN and the prostaglandin E2 system, selectively enhance 
CTL numbers but reduce Tregs in the TME, thereby 
uniformly sensitizing tumors for the therapeutic effec-
tiveness of PD-1 blockers and DC vaccines. This is being 
further evaluated in patients with melanoma, colorectal 
cancer, and ovarian cancer in a new NCI-funded pro-
gram project (P01). The combination of an αDC1 vaccine 
(αDC1 loaded with tumor blood vessel-targeting anti-
genic peptides [43]) or with desatinib or with chemokine 
modulation followed by anti-PD-1 therapy are being 
investigated in melanoma patients with primary PD-1 
resistance (NCT01876212 and NCT04093323).
Fig. 2 T-cell intrinsic mechanisms of resistance to PD1 checkpoint blockade
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Emergent strategies—session
Neoadjuvant immunotherapy—less is more
In preclinical models, neoadjuvant immunotherapy 
has been shown to activate a broader and more diverse 
range of tumor-resident T cell clones compared with 
adjuvant treatment, thereby inducing a broader immune 
response. For example, in the OpACIN trial, neoadjuvant 
treatment with ipilimumab plus nivolumab resulted in 
expanded more tumor-resident T cell clones than when 
given as adjuvant therapy [44]. After a median follow-up 
of 4 years, none of the seven patients with a pathologic 
response in the neoadjuvant arm had relapsed [45]. Esti-
mated 4-year RFS rate was 60% in both the neoadjuvant 
and adjuvant arms while, the 4-year OS rates were 90% 
and 70%, respectively.
The toxicity of the neoadjuvant ipilimumab plus 
nivolumab dosing schedule in the OpACIN trial was 
significant and so the OpACIN-neo trial was designed 
to identify an equally effective but more tolerable dos-
ing schedule of ipilimumab plus nivolumab. This was an 
open-label trial in which patients with resectable stage III 
melanoma were randomized to one of three different ipil-
imumab plus nivolumab dosing regimens [46]. Of these, 
two cycles of ipilimumab 1 mg/kg plus nivolumab 3 mg/
kg every 3 weeks was identified as tolerable and effective, 
inducing a pathological response in 77% of patients. At 
2-year follow-up, almost all high-grade adverse events 
had resolved to ≤ grade 1, except for grade 2 endo-
crinopathies. More than 80% of patients were relapse-free 
at 2-years without adjuvant treatment, and RFS remained 
significantly higher for patients with pathologic response 
versus non-responders (97% versus 36%). Only one of 
64 patients with a pathological response had relapsed. 
Pathologic response appears to be the strongest predictor 
for RFS. However, high baseline TMB and IFN-γ signa-
ture expression might also predict RFS and help identify 
patients that would benefit from neoadjuvant ipilimumab 
plus nivolumab [46].
PRADO is an extension cohort of the OpACIN-
neo study, one aim of which is to assess personalized 
response-driven adjuvant therapy. At a minimum of 
12 weeks follow-up, 70 of 99 patients (71%) had a path-
ological response in the index lymph node [47]. Sixty 
patients (61%) had major pathologic response in the 
index lymph node and did not undergo therapeutic 
lymph node dissection. These patients had fewer surgery-
related adverse events and higher quality-of-life scores.
Neoadjuvant therapy is an active area of research with 
numerous ongoing trials assessing different immunother-
apy combinations. The International Neoadjuvant Mela-
noma Consortium is developing recommendations to 
ensure alignment of trial designs and correlative analyses 
across many of these studies [48].
What are new ways to think about immunotherapy 
combinations for melanoma?
When we attempt to address the question of whether 
combination immunotherapy is better than single 
agent therapy, the typical approach is to assess whether 
response or survival are improved by treatments in 
combination as compared to single agents. However, 
there are other ways to think about how to develop 
combinations in melanoma. These include the pos-
sible de-escalation of combinations, in which compo-
nents of the combination are discontinued at certain 
times based on clinical events (response or toxicity) 
and treatment is continued as monotherapy. In this sce-
nario, clinical trials may be initiated with several drugs 
in combination, with some stopped or substituted and 
treatment adapted over time, depending on initial 
responsiveness.
Nivolumab and ipilimumab is the most investigated 
immunotherapy combination, with 5-year OS data avail-
able [49]. Lessons learned from this combination may be 
relevant to the development of future combinations with 
newer drugs. With nivolumab and ipilimumab, survival 
outcomes appear to be similar even among patients who 
discontinue treatment early because of adverse events 
[49, 50]. Similarly, in the adjuvant setting after resec-
tion or radiation of stage IV melanoma, nivolumab plus 
ipilimumab increased RFS compared with placebo even 
though patients only received a median of two doses of 
the combination [51]. This suggests that a short dura-
tion of combination therapy may be as effective as longer 
treatment, especially in the context of a high level of side 
effects.
Following these data, a logical question arose; what 
about stopping combination immunotherapy after ini-
tial treatment benefit? This question was prospectively 
assessed in the Adaptively Dosed ImmunoTherapy 
(Adapt-IT) study, in which 60 patients with unresectable 
stage III/IV melanoma received two doses of nivolumab 
1 mg/kg plus ipilimumab 3 mg/kg before an interim CT 
scan at 6-weeks [52]. Patients with a response (or stable 
disease without an increase in total measurable tumor 
burden) were switched to nivolumab alone while patients 
with an increase in tumor burden continued with the 
standard third and fourth doses of the nivolumab + ipili-
mumab combination before switching to nivolumab. 
Over two-thirds of patients (68%) had tumor shrink-
age or no growth at week 6 after one or two doses of 
the combination. The best ORR of 58% achieved in this 
trial appears comparable to that achieved with standard 
nivolumab plus ipilimumab dosing. Immunologic effects 
in blood occurred after the first dose and did not further 
increase after the second dose, so it may be that efficacy 
can be driven by a single dose of nivolumab + ipilimumab 
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and a trial to investigate a single combination dose is 
under development.
Moving forward, a de-escalation of treatment approach 
may be employed together with the possible addition 
of different treatments to patients who do not respond 
favorably after two doses of anti-PD-1 and anti-CTLA-4 
in combination. CD8 T cell imaging, circulating tumor 
DNA, or peripheral blood markers of immune activa-
tion may be used in the future to inform when treatment 
might be escalated or de-escalated.
Considering QUAD therapy to address unmet needs 
in high risk BRAF mutant melanoma
Two randomized trials have reported on triplet combi-
nation of BRAF plus MEK inhibition with PD-1/PD-L1 
therapy. In the IMSPIRE-150 trial, atezolizumab in com-
bination with vemurafenib and cobimetinib resulted in a 
significant improvement in PFS versus vemurafenib and 
cobimetinib without atezolizumab (15.1 vs 10.6 months; 
HR: 0.78; p = 0.025) [53]. There was also a suggestion of 
improved OS with the triplet combination. These results 
are comparable with those of the COMBI-I trial, in which 
combined dabrafenib and trametinib with spartali-
zumab led to an improvement in the primary endpoint 
of median PFS compared with dabrafenib and trametinib 
plus placebo [54]. However, unlike in IMSPIRE-150, 
this did not reach statistical significance (16.2 versus 
12.0 months; HR: 0.820, p = 0.042). Toxicity from the tri-
plet regimens was substantial in both these studies, with 
over 70% of patients having grade ≥ 3 treatment-related 
adverse events. However, most were events known to 
occur with targeted therapy and management of these 
events is feasible. Thus, the value of the triplet approach 
to the general melanoma patient population remains 
unclear.
Compared with other landmark trials of targeted and 
immunotherapy that underpin the current standard of 
care, the PFS seen with the triplet combinations in these 
trials was generally favorable. However, OS data were not 
impressive compared to that seen in other trials, even of 
PD-1 monotherapy, and do not appear to be compara-
ble with OS achieved with nivolumab plus ipilimumab. 
Thus, although BRAF plus MEK inhibition and anti-PD-1 
plus anti-CTLA-4 are backbone therapies in melanoma, 
the BRAK/MEK/PD-1 triplet combination has not pro-
gressed the treatment landscape.
Patients with a high TMB or T cell-inflamed gene 
expression profile are more likely to respond to immuno-
therapy [27]. Similarly, in the safety run-in and biomarker 
cohorts of the COMBI-I trial, patients with shorter PFS 
were those with low TMB and low T cell-inflamed gene 
expression profile [55]. This suggests the triplet regimen 
may augment responses in those patients already likely to 
respond.
The optimal use of targeted and immunotherapy 
remains an open question. One possibility is that a more 
nuanced sequential use of targeted and immunotherapy 
may be more beneficial than the type of upfront triplet 
combination approach investigated in IMSPIRE-150 and 
COMBI-I. For instance, early data from the SECOMBIT 
trial has suggested a ‘sandwich’ approach of 8  weeks of 
targeted therapy (encorafenib plus binimetinib) followed 
by immunotherapy (nivolumab and ipilimumab) until 
disease progression before switching back to targeted 
therapy may be promising [56].
There is still an unmet need for those 50% of patients 
who do not achieve 5-year OS on combined immuno-
therapy, with existing therapies seeming to benefit the 
same subset of patients. One consideration is that MEK 
inhibition may be having a deleterious role in the com-
bination by dampening T cell activation and recon-
sideration of its role in targeted and immunotherapy 
combinations is needed. One attempt to answer this is 
the planned QUAD study which will include two dose 
cohorts: triplet therapy of BRAF inhibitor plus anti-
PD-1 and low-dose anti-CTLA-4 and quadruple therapy 
of combined BRAF inhibitor, MEK inhibitor, anti-PD-1 
and anti-CTLA-4. One of these regimens will then be 
assessed in higher-risk patients (e.g., with symptomatic 
brain metastases, elevated LDH with liver metastases, or 
sum of longest diameters of target lesions > 44 mm).
Development of novel antibodies targeting regulatory T 
cells in cancer
CD25 is the high affinity subunit of the IL-2 receptor and 
is highly expressed on Tregs and transiently upregulated 
on activated T effector cells (Teffs) in  vitro. In murine 
tumors, CD25 is primarily restricted to Tregs with min-
imal expression on Teff cells. In humans, CD25 is pref-
erentially expressed on tumor infiltrating Foxp3+ Treg 
cells. Similar to mouse models, CD25 expression was 
significantly higher on CD4+FoxP3+ Treg cells relative 
to CD4+FoxP3− and CD8+ T cells within the studied 
tumor subtypes of advanced melanoma, early NSCLC, 
and renal cell carcinoma.
However, CD25 was largely dropped as a therapeu-
tic target. In mice, anti-CD25 as an intervention against 
established tumors failed to delay tumor growth or pro-
long survival and did not enhance the activity of immu-
notherapies. This has been attributed to ineffective 
intratumoral Treg cell depletion due to upregulation of 
the inhibitory Fcγ receptor IIb at the tumor site. Use of an 
anti-CD25 antibody engineered with enhanced binding 
to activating Fcγ receptors and antibody-dependent cell-
mediated cytotoxicity (ADCC) led to effective depletion 
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of tumor-infiltrating Tregs and increased Teff to Treg cell 
ratios [57]. Fc-optimized anti-CD25 also synergized with 
anti-PD-1 to reject established tumors with no evidence 
of immune-related toxicity.
Clinical anti-CD25 antibodies (daclizumab, basi-
liximab) block the IL-2/IL-2R interaction, as does the 
αCD25-m2a antibody (PC61 clone). However, bystander 
IL-2 receptor signaling blockade on non-depleted effec-
tor T cells limits their antitumor activity. A depleting/
non-IL-2 blocking anti-CD25 antibody could in theory 
be more effective against tumors. A next-generation anti-
CD25 antibody optimized to deplete Treg cells while 
preserving IL-2-STAT5 signaling on effector T cells has 
shown potent single dose activity, which is dependent on 
the ability of effector cells to sense endogenous IL-2 [58].
The first non-IL-2 blocking anti-human CD25 anti-
body to be developed is RG6292. This targets CD25 high 
Tregs without interfering with IL-2 signaling while afuco-
sylated human IgG1 mediates enhanced ADCC. RG6292 
preferentially depletes Tregs in peripheral blood mono-
nuclear cells and human tumor samples. RG6292 also 
depletes Tregs and activate effector cells in tumors from 
humanized mice. A phase 1 study of RG6292 is ongo-
ing to assess the safety, efficacy, pharmacodynamics, and 
pharmacokinetics in patients with advanced solid tumors 
(NCT04158583).
Oncolytic virus combination with checkpoint inhibition
Many viruses have been investigated as anticancer agents 
based on their ability to induce oncolysis. T-VEC is an 
oncolytic virus derived from the Herpes Simplex Virus-1 
(HSV-1) strain JS1. Several genetic modifications have 
been made to T‐VEC to enhance tumor cell selectivity, 
restore antigen presentation, and enhance immune rec-
ognition of HSV‐infected tumor cells while minimizing 
toxicity. Because of its favorable safety profile and onco-
lytic properties, T‐VEC is a candidate for use in combina-
tion with checkpoint‐blockade.
T-VEC is being assessed in combination with ipili-
mumab versus ipilimumab alone for advanced mela-
noma. In the primary analysis, conducted approximately 
6 months after the last patient was enrolled, the ORR was 
significantly higher in T-VEC plus ipilimumab treated 
patients versus ipilimumab alone (39% vs 18%; odds ratio, 
2.9; 95% CI 1.5–5.5; P = 0.002) [59]. Moreover, responses 
were not limited to injected lesions as decrease in visceral 
lesions was observed in 52% of patients in the combina-
tion arm and 23% in the ipilimumab arm. Combination 
treatment was tolerable and not associated with unex-
pected adverse events or an increase in the incidence 
or severity of adverse events for either agent. At 4-year 
follow-up, responses were durable and had remained 
stable between 3 and 4  years. PFS trended in favor of 
the combination arm but was not significantly differ-
ent (HR, 0.81; 95% CI 0.54–1.25, P = 0.23). Median OS 
and median duration of response had not been reached. 
Patients treated with ipilimumab alone were more likely 
to receive subsequent anticancer therapy and to receive 
the therapy earlier, which may confound OS analysis. In 
a post-hoc BRAF V600 mutation subgroup analysis, there 
was a numerical PFS improvement for the wild-type sub-
group, an observation worthy of further investigation. No 
additional safety signals were observed in longer-term 
follow-up.
In the phase Ib single-arm part of the trial, the combi-
nation of T‐VEC plus pembrolizumab resulted in an ORR 
of 62% with a complete response rate of 33%, and no 
dose‐limiting toxicities were observed [60]. In a follow‐up 
efficacy analysis of the phase Ib part after a median fol-
low‐up time of 36.8 months, ORR was 67%, Median OS 
was not estimable, and 3-year OS rate was 71.4%.
T-VEC has been combined with pembrolizumab in the 
pivotal phase Ib/IIIMASTERKEY‐265 trial. However, the 
trial has recently been stopped for futility, necessitat-
ing our rethinking of further development of oncolytic 
viruses, including biomarkers for better patient selection.
Exploring the potential of dendritic cell therapy 
for the treatment of advanced melanoma from monocyte 
dendritic cells to myeloid dendritic cells
DCs can initiate and direct adaptive immune responses. 
In DC vaccination, DCs are educated ex vivo to present 
tumor antigens and are administered to the patient with 
the aim of inducing a tumor-specific immune response. 
However, monocyte-derived DCs (moDCs) may not be 
the best source for DC-based immunotherapy, due to 
decreased migratory capacities towards the site of T-cell 
interaction by exhaustion of the cells, and evidence of 
clinical antitumor activity with moDC vaccination is 
limited.
Synthetic mRNA electroporated moDCs (TriMixDC-
MEL) administered by intravenous administration 
showed improved antitumor activity with durable disease 
control in patients with advanced melanoma [61]. Simi-
larly, data from an adjuvant trial in patients with stage 
III/IV melanoma showed that TriMixDC-MEL was toler-
able and may offer protection against disease recurrence, 
with an improvement in median time to non-salvageable 
recurrence [62]. Another phase II study investigated Tri-
MixDC-MEL in combination with ipilimumab in patients 
with pretreated advanced melanoma. Six-month dis-
ease control rate was 51% and the ORR was 38%. These 
responses were durable, with seven complete responses 
and one partial tumor response ongoing after a median 
follow-up of 36 months [63].
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Myeloid DCs (myDCs) have been shown to have a piv-
otal role in initiating antigen-specific antitumoral immu-
nity. They are essential for priming antitumor T-cell 
responses and for relicensing antitumor T lymphocytes 
to eradicate tumor cells within the TME. Exclusion of 
myDCs from the TME may also be a tumor-intrinsic 
mechanism of immune evasion. MyDCs may also syner-
gize with checkpoint inhibitor therapy. Anti-PD-1 check-
point blockade requires the crosstalk between T cells and 
DCs, in particular cDC1 [64]. Human myDCs exist in two 
subsets that are differentiated by expression of either the 
BDCA-1 or BDCA-3 surface marker. In the myDAvlpNi 
trial, patients with advanced cancers received intra-
tumoral combinatorial administration of unmanipu-
lated CD1c (BDCA-1+) myDCs plus ipilimumab and 
avelumab in combination with intravenous low-dose 
nivolumab [65]. Tolerability was manageable with mainly 
injection-site reactions, but systemic immune-related 
adverse events were observed (pneumonitis, colitis, and 
bullous pemphigoid). Responses were seen in injected 
lesions but with little indication of activity elsewhere, 
other than in one patient with melanoma.
A cell product including both BDCA-1+ and BDCA3+ 
myDCs was then developed and assessed in combina-
tion with T-VEC. In the myTVDC trial, 12 patients 
were treated with intratumoral TVEC and CD1c (either 
BDCA-1+ alone or BDCA-1+ and BDCA-3+) myDCs 
[66]. Treatment appeared to be feasible and tolerable and 
resulted in signs of antitumor activity in injected as well 
as non-injected lesions. Based on preliminary data from 
these ongoing trials, intratumoral injection of myDCs 
with other immunotherapies is associated with manage-
able toxicity. These and other trials in different tumor 
types and associated translational research may provide 
better insight into the biology of myDCs and open new 
avenues for combinatorial treatment strategies (Fig. 3).
Conclusions
Advances in molecular targeted therapy and immune 
checkpoint inhibition have led to unprecedented 
improvement in overall survival for patients with 
advanced melanoma. The use of immunotherapies, espe-
cially immune checkpoint inhibitors including PD1/
PD-L1 and CTLA-4, as well as antagonists or agonists 
of other T cells immune regulatory receptors, and com-
binations with targeted BRAF and MEK inhibitors and 
novel agents such as oncolytic viruses have significantly 
improved outcomes for many patients with metastatic 
melanoma. Increased use of systemic treatments in the 
neoadjuvant and adjuvant settings may also help improve 
long-term outcomes for patients.
Despite these improvements, additional therapeutic 
approaches are needed to overcome resistance, develop 
novel biomarker strategies, and overall to advance 
Fig. 3 Schematic outline of the myDCTV phase I clinical trial
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precision medicine. Better understanding of the TME 
and host immune response may lead to development of 
biomarkers that help identify patients for the best treat-
ment option, as well as new treatments and new combi-
nation strategies. Approaches to overcome resistance and 
to potentiate the immune response are being developed. 
Increasing evidence emerges that tissue and blood-based 
biomarkers can predict the response to a therapy. Predic-
tive biomarkers can be considered for patients’ stratifica-
tion or selection of patients who will most likely achieve 
favorable clinical outcome.
Here we reviewed approaches evaluating novel immu-
nomodulatory agents and recent insights into genetic and 
phenotypic characterization of specimens from patients 
with melanoma to develop robust biomarkers to guide 
clinical decision-making.
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